Why it is critical to recognize GA at first sight

GA is an advanced form of age-related macular degeneration (AMD).1-3 It is a leading cause of significant vision loss worldwide.1,4,5

While lesion growth in GA may appear to proceed slowly, disease progression is relentless and irreversible.5-8 Of the 397 patients who developed central GA, the median time to foveal encroachment was only 2.5 years from diagnosis according to a prospective AREDS study (N=3640).6 It is critical to diagnose and refer early because the damage is progressive and associated with irreversible vision loss.3,5,7-9

Resources for You

Downloadable resources to help you learn more about GA diagnosis and referral.

Resources for Patients

Downloadable resources to help patients and their caregivers learn more about GA.

Apellis is a global biopharmaceutical company that leverages courageous science and creativity. We are committed to addressing the unmet needs of patients and eye care professionals worldwide.

Explore the impact of GA on
your patients' quality of life.

Explore new territory in GA
Stay up-to-date with the latest news about GA and receive updates from Apellis.

References: 1. van Lookeren Campagne M, LeCouter J, Yaspan BL, Ye W. Mechanisms of age-related macular degeneration and therapeutic opportunities. J Pathol. 2014;232:151-164. doi:10.1002/path.4266. 2. Gehrs KM, Anderson DH, Johnson LV, Hageman GS. Age-related macular degeneration—emerging pathogenetic and therapeutic concepts. Ann Med. 2006;38(7):450-471. doi:10.1080/07853890600946724. 3. Fleckenstein M, Mitchell P, Freund KB, et al. The progression of geographic atrophy secondary to age-related macular degeneration. Ophthalmology. 2018;125:369-390. doi:10.1016/j.ophtha.08.038. 4. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106-116. doi:10.1016/S2214-109X(13)70145-1. 5. Boyer DS, Schmidt-Erfurth U, van Lookeren Campagne M, Henry EC, Brittain C. The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target. Retina. 2017;37(5):819-835. doi:10.1097/iae.0000000000001392. 6. Lindblad AS, Lloyd PC, Clemons TE, et al; Age-Related Eye Disease Study Research Group. Change in area of geographic atrophy in the age-related eye disease study: AREDS report number 26. Arch Ophthalmol. 2009;127(9):1168-1174. doi:10.1001/archophthalmol.2009.198. 7. Holz FG, Strauss EC, Schmitz-Valckenberg S, van Lookeren Campagne M. Geographic atrophy: clinical features and potential therapeutic approaches. Ophthalmology. 2014;121(5):1079-1091. doi:10.1016/j.ophtha.2013.11.023. 8. Sunness JS, Margalit E, Srikumaran D, et al. The long-term natural history of geographic atrophy from age-related macular degeneration: enlargement of atrophy and implications for interventional clinical trials. Ophthalmology. 2007;114(2):271-277. doi:10.1016/j.ophtha.2006.09.016. 9. American Optometric Association. AOA Comprehensive adult eye and vision examination. Quick Reference Guide: Evidence Based Clinical Practice Guideline. 1st ed. 2015. Accessed June 29, 2022. https://www.aoa.org/documents/EBO/Comprehensive_Adult_Eye_and_Vision%20QRG.pdf